Doĭchinov A, Shtereva T, Bŭchvarova V, Khristova V, Mikhalev A
Vutr Boles. 1986;25(2):68-72.
Eleven patients with immune-complex diseases were studied, that had been subjected to a total of 96 plasmaphereses during the day. The quantitative changes were followed up that developed in the active factors of coagulation after plasmapheresis. The results revealed that the plasma exchange, applied to the patients studied, induced the following changes: For factor I (fibrinogen)--mean = 2.39 +/- 1.19 g% (p greater than 0.005); for factor II (prothrombin)--mean = 55.5 +/- 20.9% (p less than 0.001); for factor V (proaccelerin)--mean = 97.6 +/- 13.8% (p greater than 0.01); for factor VII (proconvertin)--mean = 106.8 +/- 8.0% (p greater than 0.01); for factor VIII (AHG A)--mean = 64.5 +/- 22.7% (p less than 0.01); for factor IX (AHG B)--mean = 51.58 +/- 26.0% (p less than 0.001); for factor X--mean = 46.4 +/- 18.5% (p less than 0.001) and for factor XII--mean = 27.0 +/- 23.8% (p less than 0.001). That should be given consideration for the indications of the patients and their pretreatment for plasmapheresis.
对11例免疫复合物疾病患者进行了研究，这些患者在当天共接受了96次血浆置换。对血浆置换后凝血活性因子发生的定量变化进行了随访。结果显示，对所研究的患者进行血浆置换引起了以下变化：因子I（纤维蛋白原）——平均值 = 2.39 +/- 1.19 g%（p>0.005）；因子II（凝血酶原）——平均值 = 55.5 +/- 20.9%（p<0.001）；因子V（前加速素）——平均值 = 97.6 +/- 13.8%（p>0.01）；因子VII（前转变素）——平均值 = 106.8 +/- 8.0%（p>0.01）；因子VIII（抗血友病球蛋白A）——平均值 = 64.5 +/- 22.7%（p<0.01）；因子IX（抗血友病球蛋白B）——平均值 = 51.58 +/- 26.0%（p<0.001）；因子X——平均值 = 46.4 +/- 18.5%（p<0.001）；因子XII——平均值 = 27.0 +/- 23.8%（p<0.001）。这在患者血浆置换的适应证及其预处理方面应予以考虑。
